Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
GenSight Biologics said cash and cash equivalents were EUR0.7 million at Sept. 30, 2026, versus EUR1.7 million at June 30. It also said net funding needs are estimated at about EUR16 million and that a going-concern material uncertainty remains.
The company said cash collected from paid early access programs was €6.5 million and net cash used in operating activities fell 37% to €1.6 million. It also said manufacturing technology transfer to Catalent was completed and REVISE remains on track for a December 2026 last patient.